Inherent Biosciences
Inherent Biosciences is a biotechnology company pioneering epigenetic medicine for complex diseases. Their epigenetic platform detects dysregulation across multiple genes and pathways to create a new category of diagnostics and therapeutics, transforming how complex diseases like infertility are diagnosed and treated. Their flagship product, Path SpermQT, is an epigenetic sperm quality test that identifies poor fertility outcomes not detected by standard semen analysis. It uses AI and epigenetics to assess gene function related to fertility, categorizing sperm quality and correlating it with IUI or IVF outcomes to guide treatment decisions. The company aims to remove guesswork in diagnosing and treating complex diseases, starting with reproductive health.
Inherent Biosciences
Inherent Biosciences is a biotechnology company pioneering epigenetic medicine for complex diseases. Their epigenetic platform detects dysregulation across multiple genes and pathways to create a new category of diagnostics and therapeutics, transforming how complex diseases like infertility are diagnosed and treated. Their flagship product, Path SpermQT, is an epigenetic sperm quality test that identifies poor fertility outcomes not detected by standard semen analysis. It uses AI and epigenetics to assess gene function related to fertility, categorizing sperm quality and correlating it with IUI or IVF outcomes to guide treatment decisions. The company aims to remove guesswork in diagnosing and treating complex diseases, starting with reproductive health.
TL;DR
Company: Inherent Biosciences — epigenetic diagnostics & therapeutics
Location: Salt Lake City, Utah
Founded: 2019
Flagship product: Path SpermQT (epigenetic sperm quality test)
Focus: Male reproductive health (infertility) and broader complex diseases
NIH/NSF grant funding; Series A led by Propel Bio Partners
Company Overview
Problem Domain
Diagnostics and therapeutics for complex diseases with initial focus on male infertility and reproductive health.
Founded
2019
Industry
Biotechnology
Funding Track Record
1900000
Fast-Track SBIR grant reported as $1.9M
Series A led by Propel Bio Partners with participation from Portfolia and Alliance of Angels
Seed round led by Morning Star Foundation with participation from angel investors and early-stage VCs
Investor Signal
“Received government grant funding (NIH, NSF) and completed a Series A led by Propel Bio Partners”